Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Prior treatment

• Prior autologous stem cell transplant unless ≥ 3 months after transplant, prior chimeric cell therapy unless ≥ 6 months after cell infusion, prior allogeneic stem cell transplant ≤ 6 months before the first dose of the study drug
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply

Other illness

• Prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer
• Require ongoing systemic treatment for any other malignancy or systemic corticosteroid treatment
• Current or history of central nervous involvement

• Provision of signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
• Adequate hematologic, coagulation, renal, pancreatic, and hepatic function, and measurable disease according to disease-specific criteria, as applicable
• Phase 1: Confirmed diagnosis of R/R Marginal Zone Lymphoma (MZL), Follicular Lymphoma (grade 1-3a), Waldenström Macroglobulinemia (WM), non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL), Richter's transformation to DLBCL, MCL, or CLL/SLL
• Phase 2: Confirmed diagnosis of MCL, or CLL/SLL
• Highly effective method of birth control during study treatment period, and for ≥ 30 days after the last dose of the study drug